BOUNDLESS BIO, INC. Research and Development Expense
BOUNDLESS BIO, INC. (BOLD) reported Research and Development Expense of $13.97 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-07
- BOUNDLESS BIO, INC. research and development expense for the quarter ending 2026-06-30 was $13.97M, a 14.36% increase year-over-year.
- BOUNDLESS BIO, INC. research and development expense for the quarter ending 2026-03-31 was $9.73M, a 19.81% decline year-over-year.
- BOUNDLESS BIO, INC. research and development expense for the quarter ending 2025-12-31 was $9.82M, a 26.27% decline year-over-year.
- BOUNDLESS BIO, INC. research and development expense for the quarter ending 2025-09-30 was $10.67M, a 24.25% decline year-over-year.
- BOUNDLESS BIO, INC. research and development expense for fiscal 2025 was $44.84M, a 18.86% decline from fiscal 2024.
- BOUNDLESS BIO, INC. research and development expense for fiscal 2024 was $55.27M, a 29.62% increase from fiscal 2023.
- BOUNDLESS BIO, INC. research and development expense for fiscal 2023 was $42.64M.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $13.97M 10-Q · filed 2026-08-07 | $23.71M 10-Q · filed 2026-08-07 | $33.52M derived: sum of 3 quarters · filed 2026-08-07 | $44.20M derived: sum of 4 quarters · filed 2026-08-07 |
| 2026-03-31 | $9.73M 10-Q · filed 2026-05-08 | $19.55M derived: sum of 2 quarters · filed 2026-05-08 | $30.22M derived: sum of 3 quarters · filed 2026-05-08 | $42.44M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-12-31 | $9.82M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $20.49M derived: sum of 2 quarters · filed 2026-03-09 | $32.71M derived: sum of 3 quarters · filed 2026-08-07 | $44.84M 10-K · filed 2026-03-09 |
| 2025-09-30 | $10.67M 10-Q · filed 2025-11-05 | $22.89M derived: sum of 2 quarters · filed 2026-08-07 | $35.03M 10-Q · filed 2025-11-05 | $48.34M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-06-30 | $12.22M 10-Q · filed 2026-08-07 | $24.36M 10-Q · filed 2026-08-07 | $37.67M derived: sum of 3 quarters · filed 2026-08-07 | $51.76M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-03-31 | $12.14M 10-Q · filed 2026-05-08 | $25.45M derived: sum of 2 quarters · filed 2026-05-08 | $39.54M derived: sum of 3 quarters · filed 2026-05-08 | $54.28M derived: sum of 4 quarters · filed 2026-05-08 |
| 2024-12-31 | $13.31M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $27.40M derived: sum of 2 quarters · filed 2026-03-09 | $42.14M derived: sum of 3 quarters · filed 2026-03-09 | $55.27M 10-K · filed 2026-03-09 |
| 2024-09-30 | $14.09M 10-Q · filed 2025-11-05 | $28.82M derived: sum of 2 quarters · filed 2025-11-05 | $41.95M 10-Q · filed 2025-11-05 | $52.37M derived: sum of 4 quarters · filed 2025-11-05 |
| 2024-06-30 | $14.73M 10-Q · filed 2025-08-05 | $27.86M 10-Q · filed 2025-08-05 | $38.28M derived: sum of 3 quarters · filed 2025-08-05 | $49.92M derived: sum of 4 quarters · filed 2025-08-05 |
| 2024-03-31 | $13.13M 10-Q · filed 2025-05-09 | $23.54M derived: sum of 2 quarters · filed 2025-05-09 | $35.19M derived: sum of 3 quarters · filed 2025-05-09 | $46.26M derived: sum of 4 quarters · filed 2025-05-09 |
| 2023-12-31 | $10.41M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $22.06M derived: sum of 2 quarters · filed 2025-03-27 | $33.13M derived: sum of 3 quarters · filed 2025-03-27 | $42.64M 10-K · filed 2025-03-27 |
| 2023-09-30 | $11.64M 10-Q · filed 2024-11-07 | $22.72M derived: sum of 2 quarters · filed 2024-11-07 | $32.22M 10-Q · filed 2024-11-07 | |
| 2023-06-30 | $11.07M 10-Q · filed 2024-08-12 | $20.58M 10-Q · filed 2024-08-12 | ||
| 2023-03-31 | $9.50M 10-Q · filed 2024-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| TALPHERA, INC. (TLPH) | United States | $0.060B | |
| CalciMedica, Inc. (CALC) | United States | $0.061B | -1.42 |
| Skye Bioscience, Inc. (SKYE) | United States | $0.061B | -0.48 |
| Annovis Bio, Inc. (ANVS) | United States | $0.056B | -1.58 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |
| Rein Therapeutics, Inc. (RNTX) | United States | $0.063B | -1.76 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| HYPERION DEFI, INC. (HYPD) | United States | $0.065B |